Gensight Biologics SA

As of December 31, 2024, Gensight Biologics SA carries a market capitalization of 33.79M, placing it among publicly traded companies globally. Its enterprise value stands at 45.74M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Gensight Biologics SA's next confirmed earnings release is scheduled for March 19, 2027.

As of December 31, 2024, Gensight Biologics SA has 122.42M shares outstanding.

These figures are as of December 31, 2024.

As of December 31, 2024, Gensight Biologics SA maintains a current ratio of 0.24, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2024.

As of the close on October 22, 2026, Gensight Biologics SA's stock has declined approximately 42.97% over the past 52 weeks. The 50-day moving average sits at 0.10, while the 200-day moving average is 0.09.

As of December 31, 2024, Gensight Biologics SA holds 2.46M in cash and equivalents against 14.41M in total debt, resulting in a net debt position of 10.85M. Total book value stands at -26.92M, with working capital of -17.27M providing operational flexibility.